These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 31190270)

  • 1. Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts.
    Tachtsidis A; Le AV; Blick T; Gunasinghe D; De Sousa E; Waltham M; Dobrovic A; Thompson EW
    Clin Exp Metastasis; 2019 Aug; 36(4):393-409. PubMed ID: 31190270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.
    Hassan S; Blick T; Thompson EW; Williams ED
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer.
    Bonnomet A; Syne L; Brysse A; Feyereisen E; Thompson EW; Noël A; Foidart JM; Birembaut P; Polette M; Gilles C
    Oncogene; 2012 Aug; 31(33):3741-53. PubMed ID: 22120722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
    Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
    Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
    Trapp EK; Majunke L; Zill B; Sommer H; Andergassen U; Koch J; Harbeck N; Mahner S; Friedl TWP; Janni W; Rack B; Alunni-Fabbroni M
    Mol Oncol; 2017 Nov; 11(11):1508-1526. PubMed ID: 28700115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.
    Liu X; Li J; Cadilha BL; Markota A; Voigt C; Huang Z; Lin PP; Wang DD; Dai J; Kranz G; Krandick A; Libl D; Zitzelsberger H; Zagorski I; Braselmann H; Pan M; Zhu S; Huang Y; Niedermeyer S; Reichel CA; Uhl B; Briukhovetska D; Suárez J; Kobold S; Gires O; Wang H
    Sci Adv; 2019 Jun; 5(6):eaav4275. PubMed ID: 31223646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.